Trial of Artemether-Lumefantrine alone and in combination with Ivermectin to reduce post-treatment malaria transmission (ACTIVE)
To determine the safety and impact of ivermectin, administered as single or repeated dose, in combination with artemether-lumefantrine in reducing the proportion of mosquitoes that survive and become infected after feeding on a blood meal from a malaria-infected individual.
Oficial Title: A Double Blind Randomized Controlled Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment MalariaTransmission
Artemisinin-based combination therapy effectively clears asexual malaria parasites and immature gametocytes but does not prevent post-treatment malaria transmission. IVM may reduce malaria transmission by killing mosquitoes that take blood meals from IVM treated humans. In a double-blind placebo-controlled trial, 120 asymptomatic Plasmodium falciparum parasite carriers were randomised to receive artemether-lumefantrine plus placebo (AL) or a single (AL-IVM1), or double dose (200µg/kg) ivermectin (AL-IVM2). Mosquito membrane feeding was performed 1,3, and 7 days after initiation of treatment to determine Anopheles gambiae and Anopheles funestus survival and infection rates.
Ivermectin dose: 200ug/kg
- Primary outcome: safety (timeframe 8 days)
- Secondary outcome: mosquitocidal activity
ClinicalTrials.gov Identifier: NCT01603251
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|